3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Recurrence
2
Waldenstrom Macroglobulinemia
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Hairy Cell
1
Burkitt Lymphoma
1
Interventions
Rituximab
6
Filgrastim
6
Cyclophosphamide
6
Radiotherapy
5
Cyclosporine
5
Antilymphocyte Serum
5
Peripheral Blood Stem Cell Transplantation
4
Etoposide
4
Mycophenolic Acid
3
Methylprednisolone
3
Granulocyte Colony-Stimulating Factor
3
Flow Cytometry
3
Cord Blood Stem Cell Transplantation
3
Busulfan
3
plerixafor
2
fludarabine phosphate
2
Tacrolimus
2
Polymerase Chain Reaction
2
Moxifloxacin
2
Methotrexate
2
Melphalan
2
Ipilimumab
2
Immunoenzyme Techniques
2
Dasatinib
2
CTLA-4 Antigen
2
Amplified Fragment Length Polymorphism Analysis
2
thymoglobulin
1
obatoclax
1
nelarabine
1
ibrutinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Leukemia, Hairy Cell
×
brexucabtagene autoleucel
×
Clear all
NCT05537766
2026-03-10
ZUMA-25
Gilead Sciences
Phase 2
Terminated
19 enrolled
28 charts